Uncategorized

Dthera Sciences Announces Exclusivity Period and Option Agreement for its Digital Therapeutic in the Japanese MarketDthera Sciences Announces Exclusivity Period and Option Agreement for its Digital Therapeutic in the Japanese Market

Dthera Sciences Announces Exclusivity Period and Option Agreement for its Digital Therapeutic in the Japanese Market

SAN DIEGO, CA / ACCESSWIRE / February 25, 2019 / Dthera™ Sciences (OTCQB: DTHR), a leading digital therapeutic company specialized…

6 years ago
Theralase Announces Appointment of New Chief Executive OfficersTheralase Announces Appointment of New Chief Executive Officers

Theralase Announces Appointment of New Chief Executive Officers

TORONTO, ON / ACCESSWIRE / February 25, 2019 / Theralase Technologies Inc. ("Theralase®" or the "Company") (TSXV: TLT) (OTCQB: TLTFF),…

6 years ago
ENDRA Life Sciences to Host Fourth Quarter and Full Year 2018 Results Conference Call on Monday, March 11, 2019 at 4:30 p.m. ETENDRA Life Sciences to Host Fourth Quarter and Full Year 2018 Results Conference Call on Monday, March 11, 2019 at 4:30 p.m. ET

ENDRA Life Sciences to Host Fourth Quarter and Full Year 2018 Results Conference Call on Monday, March 11, 2019 at 4:30 p.m. ET

ANN ARBOR, MICHIGAN / ACCESSWIRE / February 22, 2019 / ENDRA Life Sciences Inc. (''ENDRA'') (NASDAQ: NDRA), a developer of…

6 years ago
Intellipharmaceutics Announces Fiscal Year 2018 ResultsIntellipharmaceutics Announces Fiscal Year 2018 Results

Intellipharmaceutics Announces Fiscal Year 2018 Results

TORONTO, ON / ACCESSWIRE / February 22, 2019 / Intellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) (''Intellipharmaceutics'' or the ''Company''),…

6 years ago
Show previous Posts